Abstract
Assessment via MRI is an integral part of the management of primary brain tumors. However, reliance on imaging to determine treatment response is not without its pitfalls. Necrosis is a known late effect of radiation treatment of the brain that can mimic tumor recurrence. It is now appreciated that pseudoprogression, a similar effect, can occur after combined chemoradiotherapy and can occur more quickly and dramatically than after radiation alone. Although several adjunct imaging modalities are under investigation, none is yet widely accepted as being able to distinguish between true progression and pseudoprogression. Conversely, at disease progression, antiangiogenic therapies are frequently used and can have a rapid positive effect on imaging. These changes, increasingly known as "pseudoresponses," can occur immediately after initiating treatment, making accurate assessment of true tumor response difficult. This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response.
MeSH Terms
Antineoplastic Agents/therapeutic use
Brain/drug effects,pathology
Brain Neoplasms/diagnosis,drug therapy
Diagnosis, Differential
Diagnostic Imaging/methods
Disease Progression
Female
Humans
Image Processing, Computer-Assisted/methods
Male
Chemicals
Antineoplastic Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Clarke Jennifer L
Department of Neurological Surgery, Division of Neuro-oncology, University of California-San Francisco, 400 Parnassus Avenue, A-808, Box 0372, San Francisco, CA 94143, USA.
[email protected]
Chang Susan
References (27)
27 references, click to expand
-
Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors.
Magn Reson Imaging. 2001 Jan;19(1):89-101
PMID: 11295350
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
J Clin Oncol. 2007 Oct 20;25(30):4722-9
PMID: 17947719
-
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
J Clin Oncol. 2009 Feb 1;27(4):579-84
PMID: 19075262
-
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Cancer. 2008 Jul 15;113(2):405-10
PMID: 18484594
-
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):997-1003
PMID: 15758010
-
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
J Nucl Med. 2005 Jun;46(6):945-52
PMID: 15937304
-
Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy.
AJNR Am J Neuroradiol. 1996 Apr;17(4):737-47
PMID: 8730195
-
Transient postictal MRI changes in patients with brain tumors may mimic disease progression.
Surg Neurol. 2007 Mar;67(3):246-50; discussion 250
PMID: 17320628
-
Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8
PMID: 19056837
-
Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.
Radiology. 2000 Nov;217(2):377-84
PMID: 11058631
-
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology. 2008 Mar 4;70(10):779-87
PMID: 18316689
-
Clinical and radiographic features of peritumoral infarction following resection of glioblastoma.
Neurology. 2006 Nov 14;67(9):1668-70
PMID: 17101902
-
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
J Clin Oncol. 2008 May 1;26(13):2192-7
PMID: 18445844
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):987-96
PMID: 15758009
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
PMID: 17317837
-
Clinical applications of PET in brain tumors.
J Nucl Med. 2007 Sep;48(9):1468-81
PMID: 17704239
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007 Jan;11(1):83-95
PMID: 17222792
-
Response criteria for phase II studies of supratentorial malignant glioma.
J Clin Oncol. 1990 Jul;8(7):1277-80
PMID: 2358840
-
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
J Neurooncol. 2007 Mar;82(1):81-3
PMID: 16944309
-
Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?
AJNR Am J Neuroradiol. 1998 Mar;19(3):407-13
PMID: 9541290
-
Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy.
J Nucl Med. 2008 May;49(5):694-9
PMID: 18413375
-
Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue.
AJNR Am J Neuroradiol. 2000 May;21(5):901-9
PMID: 10815666
-
Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET.
J Neurooncol. 2007 May;82(3):305-11
PMID: 17120157
-
Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.
AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9
PMID: 14970018
-
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
J Clin Oncol. 2008 Oct 1;26(28):4659-65
PMID: 18824712
-
Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.
AJNR Am J Neuroradiol. 2005 Sep;26(8):1967-72
PMID: 16155144
-
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Neurology. 2006 Apr 25;66(8):1258-60
PMID: 16636248